Kristie L. Kahl is vice president of content at MJH Life Sciences, overseeing CURE®, CancerNetwork®, the journal ONCOLOGY, Targeted Oncology, and Urology Times®. She has been with the company since November 2017.
She is a graduate of Rider University, where she acquired a Bachelors of Art in journalism, as well as a graduate of Temple University, where she received her Masters of Science in Sports Management.
Follow Kristie on Twitter at @KristieLKahl, or email her at kkahl@mjhlifesciences.com.
FDA Approves Darzalex Combination for Newly Diagnosed Multiple Myeloma
May 8th 2018The Food and Drug Administration (FDA) granted approval to Darzalex (daratumumab) in combination with Velcade (bortezomib), melphalan and prednisone – also known as VMP – for the treatment of patients with newly diagnosed multiple myeloma who are ineligible for autologous stem cell transplant (ASCT).
High-Grade Endometrioid Endometrial Cancers Likely to Benefit from Immunotherapy
April 24th 2018Researchers evaluates microsatellite instability-high status, tumor mutation burden and high PD-L1 expression to determine which grade of tumors would benefit from immunotherapy treatment among women with endometrioid endometrial cancer.
FDA Grants Dacomitinib a Priority Review for Lung Cancer Treatment
April 4th 2018The Food and Drug Administration (FDA) granted priority review to dacomitinib for the first-line treatment of patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with EGFR-activating mutations, according to Pfizer, the drug’s manufacturer.
Women with Recurrent Ovarian Cancer Should Be Screened for Various Biomarkers
March 29th 2018Although genomic profiling successfully identifies those with microsatellite instability status who may benefit from PD-1 inhibitor therapy, a vast amount of women may be missed if they are not also tested for high tumor mutation burden too.